Medical Device | January 10, 2024
Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Subscribe To Our Newsletter & Stay Updated
